Eledon Pharmaceuticals, Inc.
ELDN · Pharmaceutical Preparations · 77.2M shares · +49%/yr ↑ shares · EDGAR filings ↗
Grade
D46Clinical/early-stage biotech — transplant-tolerance clinical, well-funded.
Strengths
- Liquidity — current ratio 7.4 (70th)
Risks
- Pre-revenue, deep losses — per metrics
- Pre-revenue/clinical-stage — history of losses & need for capital per risk factors
- Binary clinical & funding risk — per 10-K
Notable findings
- Fund exitedNotable fund(s) exited this quarter: VANGUARD GROUP INC
- Strong balance sheetStrong balance sheet — $133M cash & investments
- Notable holderHeld by 5 notable fund(s): STATE STREET CORP, GOLDMAN SACHS GROUP INC, CITADEL ADVISORS LLC +2 more (as of 2026-03-31)
Key metrics
Return on equity
-56.3%
Return on assets
-27.0%
Current ratio
7.4×
Tangible book value
$81M
Cash & investments
$133M
Insider transactions · last 18 months
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| 2026-01-10 | McBride John S. | Option exercise | 3.4K | — |
| 2026-01-10 | Hillson Jan | Option exercise | 3.4K | — |
| 2026-01-10 | Kirk Allan | Option exercise | 3.4K | — |
| 2026-01-10 | Katkin Keith | Option exercise | 8.6K | — |
| 2026-01-10 | Lee June | Option exercise | 3.4K | — |
| 2026-01-10 | Robinson James A. Jr. | Option exercise | 3.4K | — |
All non-derivative Form 4 activity (SEC), newest first.
Notable events (8-K)
| Date | Items | |
|---|---|---|
| 2026-06-22 | 5.03Shareholder voteExhibits | filing ↗ |
| 2026-05-13 | ResultsExhibits | filing ↗ |
| 2026-03-19 | ResultsExhibits | filing ↗ |
| 2026-01-02 | 3.02Exhibits | filing ↗ |
| 2025-11-14 | ResultsExhibits | filing ↗ |
| 2025-11-13 | Material agreementExhibits | filing ↗ |
| 2025-11-07 | ResultsReg FDExhibits | filing ↗ |
| 2025-08-14 | ResultsNon-reliance/restatementExhibits | filing ↗ |
Recent filings
| Form | Filed | Period | Accession |
|---|---|---|---|
| 8-K | 2026-06-22 | 2026-06-18 | 0001193125-26-277653 ↗ |
| 8-K | 2026-05-13 | 2026-05-13 | 0001193125-26-221658 ↗ |
| 10-Q | 2026-05-13 | 2026-03-31 | 0001193125-26-221702 ↗ |
| 8-K | 2026-03-19 | 2026-03-19 | 0001193125-26-116154 ↗ |
| 10-K | 2026-03-19 | 2025-12-31 | 0001193125-26-116164 ↗ |
| 8-K | 2026-01-02 | 2025-12-30 | 0001193125-26-000968 ↗ |
| 8-K | 2025-11-14 | 2025-11-14 | 0001193125-25-283294 ↗ |
| 10-Q | 2025-11-14 | 2025-09-30 | 0001193125-25-283275 ↗ |
| 8-K | 2025-11-13 | 2025-11-12 | 0001193125-25-278392 ↗ |
| 8-K | 2025-11-07 | 2025-11-06 | 0001193125-25-270286 ↗ |
| 10-Q | 2025-08-14 | 2025-06-30 | 0001193125-25-180906 ↗ |
| 10-Q/A | 2025-08-14 | 2025-03-31 | 0001193125-25-180904 ↗ |